Potential pharmacokinetic interactions with concurrent use of herbal medicines and a ritonavir-boosted COVID-19 protease inhibitor in low and middle-income countries
Dallas J. Smith(Centers for Disease Control and Prevention), Michelle R. Embry(Health and Environmental Sciences Institute), Richard B. van Breemen(Oregon State University), Josias H. Hamman(North-West University), Constance A. Mitchell(Health and Environmental Sciences Institute), Hellen Oketch‐Rabah(United States Pharmacopeial Convention), Wihan Pheiffer(North-West University), Syril Pettit(Papworth Hospital), Xiaochao Ma, Mary F. Paine(Washington State University Spokane), Tsitsi G. Monera-Penduka(University of Zimbabwe), Kumbukani Nyirenda(Kamuzu Central Hospital), Huichang Bi(Southern Medical University)
Cited by 6
Related Papers
Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2
|Proceedings of the National Academy of Sciences|2005|451
Evaluation of Estrogenic Activity of Plant Extracts for the Potential Treatment of Menopausal Symptoms
|Journal of Agricultural and Food Chemistry|2001|432
Current trends in drug metabolism and pharmacokinetics
|Acta Pharmaceutica Sinica B|2019|391
Human, Rat, and Mouse Metabolism of Resveratrol
|Pharmaceutical Research|2002|318
Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-κB target gene expression
|American Journal of Physiology-Gastrointestinal and Liver Physiology|2006|230